Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2026 Feb 14:awag060.
doi: 10.1093/brain/awag060. Online ahead of print.

Progression independent of relapse and MRI activity and treatment strategies in multiple sclerosis

Fabien Rollot  1   2   3   4 , Romain Casey  1   2   3   4 , Anne Kerbrat  5   6 , Gilles Edan  5   6 , Emmanuelle Le Page  5   6 , Sandra Vukusic  1   2   3   4 , Guillaume Mathey  7   8 , Elisabeth Maillart  9 , Jérôme De Sèze  10 , Jonathan Ciron  11   12 , Aurélie Ruet  13   14 , Pierre Labauge  15   16 , Caroline Papeix  17 , Helene Zephir  18 , Christine Lebrun-Frenay  19 , Gilles Defer  20 , Thibault Moreau  21 , Eric Berger  22 , Pierre Clavelou  23 , Olivier Heinzlef  24 , Eric Thouvenot  25 , Jean Pelletier  26 , Olivier Casez  27 , Bertrand Bourre  28 , Abir Wahab  29 , Solène Moulin  30 , Arnaud Kwiatkowski  31 , Thomas David  32 , Laurent Magy  33 , Jean-Philippe Camdessanché  34 , Inès Doghri  35 , Amélie Dos Santos  36 , Karolina Hankiewicz  37 , Mariana Sarov Riviere  38 , Eric Manchon  39 , Corinne Pottier  40 , Maya Tchikviladze  41 , Clarisse Scherer Gagou  42 , Camille Dahan  43 , Pierre Durozard  44 , David-Axel Laplaud  45 , Laure Michel  5   6
Affiliations

Progression independent of relapse and MRI activity and treatment strategies in multiple sclerosis

Fabien Rollot et al. Brain. .

Abstract

The impact of high-efficacy therapies (HET) on progression independent of relapse and MRI activity (PIRMA) remains poorly defined. In this context, using the French MS registry, we aimed to assess the real-life effectiveness of HET compared with moderate efficacy therapies (MET) on PIRMA in relapsing-onset MS (RMS) patients. Data were collected from RMS patients of the French MS Registry, between January, 2010 and June, 2023, with a mean follow-up of 3.7 years. RMS patients were included in the analysis if they were treated first with HET (2666 included) or MET (7833 included), and had EDSS and MRI follow-up every two years. Each outcome was studied using a propensity score framework. The primary outcome was time-to-first PIRMA. Secondary outcomes were PIRMA incidence, time-to-first confirmed disability progression (CDP), relapse-associated worsening (RAW), MRI-associated worsening (MAW) and identification of risk factors associated with PIRMA. A total of 10499 patients fulfilled the inclusion criteria. The mean (SD) age at treatment initiation was 36.4 (10.3) years, with a mean (SD) disease duration of 3.1 (5.1) years. The restricted mean survival (SD) time to first PIRMA was slightly significantly shorter in the HET group compared to the MET group (8.7 yrs (0.08) vs. 8.9 yrs (0.05) p=0.017). However, when looking at time-to-first CDP, it tend to be longer in the HET group compared to the MET group (7.6 (0.10) vs. 7.3 years (0.06); p=0.071), and it was probably linked to the shorter time-to-first RAW and MAW in the MET group (9.2 (0.06) vs 8.7 years (0.05); p<0.001 for RAW and 9.0 (0.05) vs 8.5 (0.07); p<0.001 for MAW). Baseline risk factors associated with increased PIRMA incidence in the whole population were: high EDSS, higher age at baseline and the presence of spinal cord lesions. Even if HET have a better control on disability accumulation related to disease activity than MET, our real-life study suggests that PIRMA-related mechanisms are not differentially affected by HET versus MET.

Keywords: disability; high-efficacy therapy; multiple sclerosis; progression independent of relapse and MRI activity; treatment.

PubMed Disclaimer

LinkOut - more resources